WestJet joins global initiative to support guests through the Hidden Disabilities Sunflower program Français
"Through our participation in the Hidden Disabilities Sunflower program, we are proud to further our commitment to providing convenient and accessible services that meet the unique needs of our guests," said Jacqui McGilliivray, WestJet Executive Vice-President and Chief People Officer. "The Sunflower lanyard provides a visual cue to help those with non-visible disabilities communicate their needs and navigate their environment with confidence, significantly improving their overall guest experience and making travel more accessible for them."
The Hidden Disabilities Sunflower program is a globally recognized program that uses the Sunflower symbol to help travellers make their needs known. Guests can choose to wear the Sunflower lanyard, or other Sunflower branded products such as a pin or wristband, both in airports and on WestJet flights to indicate to WestJet employees that they may have a specific need or require additional assistance.
"We are delighted to welcome WestJet to the global Hidden Disabilities Sunflower network. Non-visible disabilities can be neurological, cognitive and neurodevelopmental as well as physical, visual, auditory and including sensory and processing difficulties. They can also include respiratory, heart, rare diseases and chronic conditions such as asthma, diabetes and chronic pain. It is wonderful to see how WestJet have committed time and energy to implement the Sunflower training to ensure that travelling Sunflower wearers are recognised by their staff to receive the additional help, understanding and kindness they may need." - Paul White, CEO Hidden Disabilities Sunflower
As part of WestJet's commitment to improving accessibility, Sunflower lanyards are now available upon request at WestJet check-in counters across Canada. Guests are also encouraged to reuse their Sunflower lanyards on future flights or wherever the Sunflower is recognized and helps them receive the assistance they need.
About WestJet
WestJet took to the skies in 1996 with just over 200 employees and three aircraft operating service to five destinations. Since then, WestJet has pioneered low-cost travel in Canada, cutting airfares in half, and increasing the flying population in Canada by more than 50 per cent. Following integration with Sunwing in 2025, more than 14,000 WestJetters support nearly 200 aircraft and connect guests to more than 100 destinations across North America, Central America, the Caribbean, Europe and Asia.
As a major Canadian employer that includes WestJet Airlines, Sunwing Vacations Group and WestJet Cargo, the WestJet Group is Canada's leading low-cost airline and largest vacation provider, with a united purpose of providing affordable and accessible air and vacation travel to Canadians.
Learn more about WestJet at westjet.com/en-ca/who-we-are (also available in French)
Follow WestJet on Facebook at facebook.com/westjet
Follow WestJet on X at x.com/westjet and x.com/WestJetNews
Follow WestJet on Instagram at instagram.com/westjet/
Subscribe to WestJet on YouTube at youtube.com/westjet
About the Hidden Disabilities Sunflower:
The Hidden Disabilities Sunflower enables individuals to discreetly indicate that they have a non-visible disability and may need additional assistance, understanding, or more time.
Since Hidden Disabilities Sunflower was established in the UK in 2016, it has been adopted globally by businesses and charities to support their colleagues and customers. The Sunflower is recognized across a broad range of sectors - ranging from retail, financial services, transport including over 220 airports, travel and tourism, education, government, as well as healthcare, emergency service and entertainment.
Hidden Disabilities Sunflower is available globally and has been launched locally in Australia, Belgium, Canada, Denmark, Ireland, Latin America, Mauritius, the Netherlands, New Zealand, the UAE, the UK and USA.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Canada News.Net
32 minutes ago
- Canada News.Net
Canada's new drug pricing guidelines are industry-friendly
Share article Print article Drug pricing in Canada just got more industry-friendly. Canadian drug prices are already the fourth highest in the industrialized world. Now, with the release of new guidelines for the staff at the Patented Medicine Prices Review Board (PMPRB) at the end of June, the situation is poised to potentially get even worse. The review board is the federal agency that was set up 1987 to ensure that the prices for patented drugs are not "excessive." Up until now, one of the criteria the PMPRB used in making the decision about what was an excessive price was to compare the proposed Canadian price for a new drug with the median price in 11 other countries. The median is the 50 per cent mark; in other words, the price in half of the other countries was below what's proposed for Canada, and the price in the other half was above the proposed Canadian price. Under the new guidelines, set to take effect on Jan. 1, 2026, the Canadian price can be up to the highest in those other 11 countries. Right now, the median price in the 11 countries Canada is compared to is 15 per cent below the price of patented drugs in Canada. The highest international price, which will be the new standard, is 21 per cent above the median Canadian price, meaning Canadian prices for new drugs will be significantly higher than they otherwise would have been. Sometimes a drug is not available in any of the 11 other countries when it comes onto the Canadian market. In that case, the company can price the drug at whatever level it wants and keep it at that price until it comes up for its annual price review. The executive director of the PMPRB told the Globe and Mail that this would incentivize drugmakers to bring their products to the Canadian market first. Incentivizing drug companies may be a reasonable idea, but that's not part of the mandate of the PMPRB. As laid out in Section 83 of the Patent Act, its mandate is to ensure drug prices aren't excessive. In the past, one of the factors that the PMPRB took into account in determining if prices were excessive was the additional therapeutic value of a new drug compared to what was already on the market. The lower the value, the lower the price. In this regard, the PMPRB was advised by its Human Drug Advisory Panel, an independent group of experts. The ranking of new drugs against existing ones was also of significant value to Canadian clinicians. It helped them to decide on the best treatment option for their patients and countered the hype about new drugs that came from the manufacturers. Since the new guidelines have abandoned looking at therapeutic improvement of new drugs, that leaves only one remaining Canadian source for that type of information, the Therapeutics Letter, a bimonthly publication targeting identified problematic therapeutic issues in a brief, simple and practical manner. Complaints about prices can be made by federal, provincial and territorial health ministers and by senior officials who are authorized to represent Canadian publicly funded drug programs. " Other parties who have concerns about the list prices ... are encouraged to raise their concerns with their relevant Minister(s) of Health or Canadian publicly-funded drug program (sic)." This advice is cold comfort for people working low-wage jobs who aren't covered by provincial and territorial drug plans and don't have any access to their health minister. If there is an in-depth review of a new drug's pricing - a preparatory step to determine whether there should be a formal hearing to investigate if the price is excessive - it is only the manufacturer that is allowed to submit information to the PMPRB. Clinicians who prescribe the drug, patients who take the drug, and organizations and individuals that pay for the drug do not have that same right. Donald Trump's on-again, off-again tariffs are already threatening to drive up drug prices and make prescription drugs inaccessible to many Canadians. Higher drug prices will also almost certainly affect Canada's already limited pharmacare program. Higher prices for new drugs will make an expanded pharmacare plan more expensive and less appealing to the federal government. The new PMPRB guidelines help ensure higher drug prices and no pharmacare expansion.
Canada News.Net
32 minutes ago
- Canada News.Net
Canada's new drug pricing guidelines are industry friendly
Share article Print article Drug pricing in Canada just got more industry-friendly. Canadian drug prices are already the fourth highest in the industrialized world. Now, with the release of new guidelines for the staff at the Patented Medicine Prices Review Board (PMPRB) at the end of June, the situation is poised to potentially get even worse. The review board is the federal agency that was set up 1987 to ensure that the prices for patented drugs are not "excessive." Up until now, one of the criteria the PMPRB used in making the decision about what was an excessive price was to compare the proposed Canadian price for a new drug with the median price in 11 other countries. The median is the 50 per cent mark; in other words, the price in half of the other countries was below what's proposed for Canada, and the price in the other half was above the proposed Canadian price. Under the new guidelines, set to take effect on Jan. 1, 2026, the Canadian price can be up to the highest in those other 11 countries. Right now, the median price in the 11 countries Canada is compared to is 15 per cent below the price of patented drugs in Canada. The highest international price, which will be the new standard, is 21 per cent above the median Canadian price, meaning Canadian prices for new drugs will be significantly higher than they otherwise would have been. Sometimes a drug is not available in any of the 11 other countries when it comes onto the Canadian market. In that case, the company can price the drug at whatever level it wants and keep it at that price until it comes up for its annual price review. The executive director of the PMPRB told the Globe and Mail that this would incentivize drugmakers to bring their products to the Canadian market first. Incentivizing drug companies may be a reasonable idea, but that's not part of the mandate of the PMPRB. As laid out in Section 83 of the Patent Act, its mandate is to ensure drug prices aren't excessive. In the past, one of the factors that the PMPRB took into account in determining if prices were excessive was the additional therapeutic value of a new drug compared to what was already on the market. The lower the value, the lower the price. In this regard, the PMPRB was advised by its Human Drug Advisory Panel, an independent group of experts. The ranking of new drugs against existing ones was also of significant value to Canadian clinicians. It helped them to decide on the best treatment option for their patients and countered the hype about new drugs that came from the manufacturers. Since the new guidelines have abandoned looking at therapeutic improvement of new drugs, that leaves only one remaining Canadian source for that type of information, the Therapeutics Letter, a bimonthly publication targeting identified problematic therapeutic issues in a brief, simple and practical manner. Complaints about prices can be made by federal, provincial and territorial health ministers and by senior officials who are authorized to represent Canadian publicly funded drug programs. " Other parties who have concerns about the list prices ... are encouraged to raise their concerns with their relevant Minister(s) of Health or Canadian publicly-funded drug program (sic)." This advice is cold comfort for people working low-wage jobs who aren't covered by provincial and territorial drug plans and don't have any access to their health minister. If there is an in-depth review of a new drug's pricing - a preparatory step to determine whether there should be a formal hearing to investigate if the price is excessive - it is only the manufacturer that is allowed to submit information to the PMPRB. Clinicians who prescribe the drug, patients who take the drug, and organizations and individuals that pay for the drug do not have that same right. Donald Trump's on-again, off-again tariffs are already threatening to drive up drug prices and make prescription drugs inaccessible to many Canadians. Higher drug prices will also almost certainly affect Canada's already limited pharmacare program. Higher prices for new drugs will make an expanded pharmacare plan more expensive and less appealing to the federal government. The new PMPRB guidelines help ensure higher drug prices and no pharmacare expansion.
Globe and Mail
an hour ago
- Globe and Mail
Kiwetinohk announces upcoming second quarter 2025 earnings release
CALGARY, AB , July 24, 2025 /CNW/ - Kiwetinohk Energy Corp. (TSX: KEC) management will host a conference call on July 31, 2025 , at 8 AM MT ( 10 AM ET ) to discuss second quarter 2025 results and answer questions. Participants can listen to the conference call by dialing 1-888-510-2154 ( North America toll free) or 437-900-0527 ( Toronto and area). A replay of the call will be available until August 7, 2025 , at 1-888-660-6345 ( North America toll free) or 646-517-4150 ( Toronto and area) by using the code 92805. About Kiwetinohk Kiwetinohk produces natural gas, natural gas liquids, oil and condensate from profitable early to mid-life liquids-rich natural gas properties focused in the Montney and Duvernay formations in Alberta, Canada . Kiwetinohk's common shares trade on the Toronto Stock Exchange under the symbol KEC. Additional details are available on Kiwetinohk's website at and SEDAR+ at For more information on Kiwetinohk, please contact: Investor Relations Investor Relations email: IR@ Investor Relations phone: (587) 392-4395 Pat Carlson , Chief Executive Officer Jakub Brogowski, Chief Financial Officer
